BahamasTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.49 (0.49–0.49)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.93 (0.32–1.9)
Incidence  (includes HIV+TB) 0.071 (0.061–0.082) 18 (16–21)
Incidence (HIV+TB only) 0.022 (0.019–0.026) 5.7 (4.9–6.6)
Incidence (MDR/RR-TB)** 0.01 (<0.01–0.018) 2.4 (0.28–4.6)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.032 (0.026–0.039) 0.035 (0.027–0.042)
Males <0.01 (<0.01–<0.01) 0.035 (0.027–0.042) 0.037 (0.029–0.045)
Total <0.01 (<0.01–<0.01) 0.067 (0.061–0.073) 0.071 (0.061–0.082)
TB case notifications, 2015  
Total cases notified 62
Total new and relapse 62
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 90%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 54%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.08 (0.04–0.13)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 16 29%
          - on antiretroviral therapy 7 44%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  7
(1–14)
Estimated % of TB cases with MDR/RR-TB 11% (2.4–29) 50% (1.3–99)  
% notified tested for rifampicin resistance 54% 67% 34
MDR/RR-TB cases tested for resistance to second-line drugs   1
Laboratory-confirmed cases MDR/RR-TB: 3, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 50
Previously treated cases, excluding relapse, registered in 2014 100% 1
HIV-positive TB cases, all types, registered in 2014 67% 21
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data